Objectives: This phase 1 study investigated safety/tolerability, pharmacokinetics, and preliminary efficacy of SC-002, a delta-like ligand 3-directed antibody-drug conjugate, in advanced small cell lung cancer and large cell neuroendocrine carcinoma. Materials and methods: Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study. Results: Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response. Conclusion: SC-002 treatment was associated with systemic toxicity and limited efficacy.
- Antibody-drug conjugate
- Delta-like ligand 3
- Large cell neuroendocrine carcinoma
- Small cell lung cancer